Toronto, Ontario – TheNewswire - (September 19, 2024) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the successful completion of its annual audit under the Medical Device Single Audit Program (MDSAP), ISO 13485 Quality Management System, and EU Medical Device Regulation (MDR) requirements by Notified Body. The audit resulted in zero major nonconformities and confirmed Ventripoint Diagnostics Ltd.’s continued compliance with global quality and ...

It’s an exciting time to be a growth investor despite the current volatility.Thanks to modern brokerages, it’s easier and cheaper than ever to access a wide range of global stocks. With so many options at your fingertips, the possibilities are vast – but so is the noise.The internet is flooded with data, opinions, and analysis, making it difficult to zero in on truly promising growth stocks. Add in the constant barrage of headlines from business news outlets, and it’s easy to feel overwhelmed.That’s why sta ...

MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, Sep ...

U.S. medical device maker GE Healthcare is working with advisers to explore options for its China unit including an outright sale, a person with knowledge of the discussions said on Friday. ...

市场规模与增长 - 全球阵发性室上性心动过速(PSVT)市场2024年估值为13.5亿美元 预计2032年将达到21.2亿美元 2025至2032年复合年增长率为5.8% [1] 市场驱动因素 - 全球心血管疾病负担增加和人口老龄化趋势推高心律失常患者数量 [5][12][14][19] - 诊断和治疗技术进步 包括高分辨率3D电解剖标测系统和新型消融能量源(如脉冲场消融)的开发 [6][15][18] - 微创导管消融手术因其高成功率和治愈潜力被越来越多地采用 [13][16][22][29] - 患者和医疗提供者对PSVT的认识提高 推动更早诊断和干预 [5][19][20] 技术趋势与创新 - 人工智能和机器学习应用于心电图分析 实现前所未有的诊断精度和早期检测 [2][3][4][8][11][15] - 可穿戴和微型植入式心脏监测设备的普及 支持连续远程监测 [3][6][13][15][18] - 机器人辅助导管消融和药物洗脱球囊等先进技术提高治疗精确度和靶向给药 [15][21] - 基因疗法、干细胞研究和生物标志物发现为个性化治疗开辟新途径 [15][21] 治疗方式演变 - 导管消融作为首选治愈性程序 因其高成功率和微创特性而需求增长 [5][13][16][22][29] - 药物治疗向副作用更少的新型抗心律失常药物发展 [8][20] - 非药物干预如迷走神经操作和神经调节技术作为替代治疗方案受到关注 [10][21] - 治疗场所有向门诊和家庭护理模式转变的趋势 强调成本效益和患者便利 [13][17][20] 区域市场动态 - 北美(尤其是美国)因先进医疗基础设施和高医疗支出占据市场主导地位 [24] - 欧洲国家如德国、英国和法国凭借强大的政府支持和研发活动贡献显著份额 [25] - 亚太地区预计增长最快 受改善的医疗基础设施和人口大国需求推动 [26] - 拉丁美洲及中东非洲地区通过医疗旅游投资和现代化医疗设施开发逐步扩大市场 [27][28] 细分市场前景 - 按类型分 房室结折返性心动过速(AVNRT)作为最常见类型驱动持续需求 [10][29] - 诊断领域中 电生理(EP)测试和事件监测因精确数据和连续捕获能力而增长 [10][29] - 治疗领域内 导管消融部门预计将显著扩张 [22][29] - 终端用户方面 心脏病专科诊所和流动手术中心因转向专业化门诊护理而增长 [10][29] 行业竞争格局 - 主要参与者包括辉瑞(Pfizer)、诺华(Novartis)、赛诺菲(Sanofi)、强生(Johnson & Johnson)等制药巨头 [9] - 美敦力(Medtronic)、雅培(Abbott)、波士顿科学(Boston Scientific)等医疗设备公司在技术创新中扮演关键角色 [9][15] - 葛兰素史克(GlaxoSmithKline)和阿斯利康(AstraZeneca)等公司也参与市场竞争 [9]

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 10 Best NASDAQ Stocks to Buy For Long Term. On September 10, Bank of America Securities reiterated a Buy rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) with a price target of $650. This decision comes in spite of Intuitive Surgical, Inc.’s (NASDAQ:ISRG) stock’s recent performance, which has showed weakness. Analysts Stay Positive on Intuitive Surgical (ISRG) Despite Stock Dip On September 4, Bernstein SocGen Group also reaffirmed an Outperform ratin ...

上海活动报名： 2025医疗器械研发创新论坛 2025年9月17日， Vivani Medical 宣布已确定其 子公司 Cortigent 的分拆登记日 。根据安排，10月8日持 有公司普通股的股东将获得 Cortigent 的普通股，该公司预计将在纳斯达克以"CRGT"代码独立交易。此次分 拆标志着 Vivani 将形成"两条主线"： 一方面继续专注于微型药物植入技术，另一方面由 Cortigent 独立推进 神经植入与脑机接口产品 。 一、Vivani 拆分 Cortigent Vivani 于2025年5月 首次披露 分拆计划，并在9月确认了登记日。根据公告， 股东将按照持股比例直接获得 Cortigent 的股份 ， 预计交易将在2025年底前完成 。分拆完成后，Vivani 与 Cortigent 将分别聚焦各自的 业务领域：Vivani 致力于药物递送植入装置，而 Cortigent 将专注于神经调控和脑机接口技术。 Vivani CEO Adam Mendelsohn 表示，此次交易的战略目标是建立两家在各自领域中能够独立创造价值的公 司。公司管理层认为，分拆后各方能够获得更大的战略灵活度、资 ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of RxSight, Inc. (NASDAQ: RXST). Shareholders who purchased shares of RXST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rxsight-inc-loss-submission-form/?id=167835&from=3  CLASS PERIOD: November 7, 2024 ...

DIH Receives Notice of Additional Basis for Delisting from The Nasdaq Stock Market DIH Has Requested Hearing to Appeal before Nasdaq Hearing Panel NORWELL, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ:DHAI) received a notice on September 12, 2025, from the Listing Qualifications Staff (“Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that it had failed to regain compliance under Nasdaq Listing Rule 5450(b)(2)(A) (the “Bid Price Rule”) and, accordingly, th ...

In this article, we will take a look at some of the best options for a dividend stock portfolio.Dividends have long been a magnet for investors. A Wall Street Journal report noted that many shareholders said they didn’t rely on dividend income right now but believed dividend-paying stocks tend to offer stronger returns with lower volatility.History backs up that view. Research from Ned Davis covering the past 50 years shows that S&P 500 companies paying dividends delivered annualized returns of 9.2%, more t ...